Bisoprolol 2,5mg tablets 30

Russia

Bisoprolol

2.5 mg

Bisoprolol fumarate - 10 mg

Excipients: calcium hydrogen phosphate anhydrous - 88.75 mg, microcrystalline cellulose - 37 mg, corn starch - 11.25 mg, magnesium stearate - 1.5 mg, silicon dioxide colloidal - 1.5 mg.

Shell composition: opadrai II yellow (85F38201) - 4.5 mg (polyvinyl alcohol - 40%, titanium dioxide - 24.48%, macrogol 3350 - 20.2%, talc - 14.8%, iron oxide yellow - 0.5%, iron oxide red - 0.02%).

Selective beta ₁ -adrenergic blocker without internal sympathomimetic activity, does not have membrane-stabilizing activity. Reduces plasma renin activity, reduces myocardial oxygen demand, reduces heart rate (at rest and under load) and cardiac output, while the stroke volume is not significantly reduced. Inhibits AV conduction. It has an antianginal and hypotensive effect. In high doses (200 mg or more) can cause blockade and β ₂ Adrenergic receptors mainly in the bronchi and in the smooth muscles of the vessels.

The hypotensive effect is associated with a decrease in the minute volume of blood, sympathetic stimulation of peripheral vessels, a decrease in the activity of the renin-angiotensin system (of greater importance for patients with initial hypersecretion of renin), restoration of sensitivity in response to a decrease in blood pressure and an effect on the central nervous system.

The antianginal effect is due to a decrease in myocardial oxygen demand as a result of a decrease in heart rate and a decrease in contractility, lengthening of diastole, improvement of myocardial perfusion.

Antiarrhythmic effect is due to the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system systems, increased content of cAMP, arterial hypertension), a decrease in the rate of spontaneous excitation of the sinus and ectopic pacemakers and a slowdown in AV conduction (mainly in the antegrade and, to a lesser extent, in retrograde directions through the AV node) and along additional pathways.

Absorption - 80-90%, food intake does not affect absorption.

C _max in the blood plasma is achieved after 2-4 h. Binding to plasma proteins - 26-33%. Bisoprolol penetrates the BBB and placental barrier to a small extent; excreted in breast milk.

It is metabolized in the liver.

T _1/2 - 9-12 h. Excreted by the kidneys - 50% unchanged, less than 2% - with bile.

Arterial hypertension, prevention of angina attacks, chronic heart failure.

Acute heart failure, chronic heart failure in the stage of decompensation, cardiogenic shock, collapse, AV-blockade of II and III degrees (without a pacemaker), SSSU; sinoatrial blockade, severe bradycardia (heart rate <50 beats / min), Prinzmetal's angina, a pronounced decrease in blood pressure (systolic blood pressure <90 mm Hg), severe forms of bronchial asthma and COPD in the anamnesis, late stages of peripheral circulatory disorders, Raynaud's disease, pheochromocytoma (without the simultaneous use of alpha-blockers), metabolic acidosis, simultaneous administration of MAO inhibitors (with the exception of MAO type B inhibitors), children and adolescents under 18 years of age, hypersensitivity to bisoprolol and other beta-blockers.

Individual. For oral administration, the daily dose is 2.5-10 mg, the frequency of administration is 1 time / day. The maximum daily dose is 10 mg.

From the nervous system: weakness, fatigue, dizziness, headache, sleep disorders, mental disorders (depression, rarely hallucinations), a feeling of cold and paresthesia in the limbs.

From the cardiovascular system: orthostatic hypotension, bradycardia, impaired AV-conduction, the appearance of symptoms of heart failure, aggravation of intermittent claudication and the main clinical symptoms in Raynaud's syndrome.

From the side of the organ of vision: a decrease in the secretion of tear fluid, conjunctivitis.

From the digestive system: diarrhea, constipation, nausea, abdominal pain.

From the musculoskeletal system: muscle weakness, muscle cramps.

From the skin and subcutaneous tissues: skin itching; in some cases - increased manifestations of psoriasis, the appearance of psoriasis-like rashes.

From the respiratory system: in predisposed patients may experience symptoms of bronchial obstruction.

Other: sweating, hot flashes, impaired potency, decreased glucose tolerance in patients with diabetes, allergic reactions.

The drug should be stored in a dry, protected from light, out of the reach of children at a temperature not exceeding 25 ° C.